Physician profile
Mukesh Kumar
NPI 1295902419
$14,014.18
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $71.51 · 2021: $133 · 2022: $884 · 2023: $397 · 2024: $157 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,023 · Travel and Lodging: $2,460 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $825 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,022.50 |
| Travel and Lodging | $2,460.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $825.17 |
| Education | $356.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,527.03 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Avyxa Pharma, LLC | $3,832.73 | 2025 | |
| Janssen Scientific Affairs, LLC | $1,387.50 | 2025 | Tecvayli |
| Janssen Biotech, INC. | $384.29 | 2019-2024 | Darzalex |
| Merck Sharp & Dohme LLC | $359.44 | 2022-2025 | Keytruda, Keytruda Qlex |
| Novocure Gmbh | $250.00 | 2022 | |
| Sobi, INC | $193.14 | 2022-2023 | |
| Abbvie INC. | $138.54 | 2022-2025 | |
| Seagen INC. | $126.21 | 2022 | |
| Kite Pharma, INC. | $101.39 | 2022-2023 | |
| Gilead Sciences, INC. | $94.34 | 2023-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $82.80 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $65.62 | 2021-2022 | |
| Eisai INC. | $60.72 | 2019-2021 | |
| Amgen INC. | $49.84 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $49.57 | 2022-2023 | Injectafer |
| Terumo Bct, INC. | $36.10 | 2019 | |
| Celgene Corporation | $35.60 | 2023 | Opdualag, Pomalyst |
| Array Biopharma INC | $28.13 | 2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $27.30 | 2022 | |
| Incyte Corporation | $26.64 | 2024 | Monjuvi, Pemazyre |
| Deciphera Pharmaceuticals INC. | $18.71 | 2021 | |
| Glaxosmithkline, LLC. | $18.20 | 2021 | |
| Genentech USA, INC. | $17.65 | 2019 | |
| Adc Therapeutics America, INC. | $17.45 | 2022 | |
| Genzyme Corporation | $16.56 | 2025 | |
| Novocure INC. | $16.35 | 2025 | Optune Lua (Novottf-200t) |
| Pfizer INC. | $13.49 | 2023 | |
| Exelixis INC. | $13.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.81 | 2019 | |
| Mirati Therapeutics, INC. | $12.74 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.